Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary
Beam Therapeutics reported 2Q 2026 results in its 10-Q. Revenue was $0.5M, down from $8.5M a year earlier. Net loss attributable to Beam was $(122.7)M versus $(102.1)M, and diluted EPS was $(1.18) versus $(1.00). The company said BEACON risto-cel dosing is complete and a BLA is targeted for year-end 2026.
How this was made
The 30-second read
Why it matters
Traders can use the reported revenue, loss, and EPS to reassess near-term financial risk, while the clinical and manufacturing updates inform the probability-weighted timeline toward a potential BLA filing targeted for year-end 2026.
Market read
Company-specific 10-Q details (revenue, net loss, EPS) plus reiterated clinical milestones can move sentiment and influence expectations for funding needs and trial-driven catalysts.
What to watch
The summary does not quantify cash balance, burn rate, or dilution terms from the capital raises, which are often the key drivers of near-term price action after a 10-Q.
Background
This is a summary of Beam Therapeutics’ 2Q 2026 results and business updates filed via a 10-Q on Aug. 4, 2026.
Ticker impact
Beam reported 2Q 2026 revenue of $0.5M and a net loss of $(122.7)M, alongside BEACON risto-cel Phase 1/2 dosing completion and a year-end 2026 BLA target.
Likely downside bias on valuation and cash-burn concerns, partially offset by continued clinical progress and non-dilutive milestone revenue.
Revenue fell sharply YoY and losses widened, but the company also highlights ongoing trial progress (BEACON dosing completed, pivotal expansion cohort for BEAM-302) and a cGMP facility coming online, which may support sentiment despite weak financials.
Market effects
Reinforces ongoing high-risk, pre-commercial biotech funding dynamics and the importance of non-dilutive milestones and manufacturing readiness.
No clear regional spillover beyond US-listed biotech sentiment.
Limited, as the disclosure is company-specific and not a cross-market macro or regulatory event.
Counterpoint
Clinical milestones (BEACON dosing completion and BEAM-302 pivotal expansion) could reduce probability of program failure, which may matter more than near-term revenue collapse for traders focused on binary trial outcomes.
Key entities
- companyBeam Therapeutics Inc.
Reported 2Q 2026 financial results and provided clinical, manufacturing, and collaboration updates in its 10-Q.
- clinical_programBEACON risto-cel
Phase 1/2 dosing completed with durability metrics cited; BLA filing targeted for year-end 2026.
- clinical_programBEAM-302
Advancing into a pivotal expansion cohort per the company’s update.
